INTRODUCTION
Recent insights into the basic mechanisms involved in atherogenesis indicate that deleterious alterations of endothelial physiology, also referred to as endothelial dysfunction, represent a key early step in the development of atherosclerosis and are also involved in plaque progression and the occurrence of atherosclerotic complications. 1 One of the major risk factor for cardiovascular disease is the metabolic syndrome (MS). Its components: dyslipidemia, hypertension, insulin resistance and abdominal obesity are linked with an infl ammatory and a prothrombotic state. This could generate the cardiovascular disease, the fi rst changes being the endothelial dysfunction. ED accompanied by infl ammation in the vessel wall is characterized by increased lipoprotein oxidation, smooth muscle cell proliferation, extracellular matrix deposition, accumulation of lipid-rich material, activation of platelets, and thrombus formation. 2 Adipose tissue is no longer viewed as a passive repository for triacylglycerol storage and a source of free fatty acids (FFAs). Mature adipocytes are widely acknowledged as an active endocrine and paracrine organ secreting an ever-increasing number of mediators that participate in diverse metabolic processes. 3 More recently, adipose tissue is recognized as a rich source of proinfl ammatory mediators that may directly contribute to vascular injury, insulin resistance, and atherogenesis. These proinfl ammatory adipocytokines, or adipokines, include TNF-alpha, IL-6, leptin, plasminogen activator inhibitor-1 (PAI-1), angiotensinogen, resistin and C-reactive protein (CRP) (Fig. 1) . On the other hand, nitric oxide (NO) 4 and adiponectin confer protection against infl ammation and obesity-linked insulin resistance 5 .
ADIPONECTIN AND ENDOTHELIAL DYSFUNC-TION
Adiponectin is an adipose tissue-derived adipokine which has protective role in the initiation and progression of atherosclerosis through its anti-infl ammatory and anti-atherogenic effects. Adiponectin serum levels are decreased in obesity, type 2 diabetes, patients with coronary artery disease, etc. 6 The level of circulating adiponectin correlates positively with high-density lipoprotein (HDL) cholesterol, and negatively with infl ammatory markers, markers of insulin resistance, triglyceride-rich lipoprotein particles, and other adipokines.
Adiponectin negatively regulates the expression of TNF-alpha and CRP in adipose tissue. On the contrary, its expression is negatively regulated by TNF-alpha and IL-6. Adiponectin reduces expression of vascular and intracellular adhesion molecules (VCAM-1, ICAM-1), E-selectin, IL-8, and monocyte adhesion to human aortal endothelial cells after their stimulation with TNF-alpha. 7 The proliferation and migration of smooth muscle cells induced by platelet-derived growth factor (PDGF) is abolished or diminished by adiponectin action as inhibition of activation of nuclear factor kappa B in endothelial cells. This effect is partially mediated by its ability to support the action of cyclic adenosine monophosphate -proteinkinase A system (cAMP-PKA).
In endothelial cells, adiponectin inhibits the production of reactive oxygen species (ROS) induced by high levels of glucose via the above mentioned cAMP-PKA system. Adiponectin inhibits macrophage transformation to foam cells and reduces the intracellular content of cholesterol esters via suppression of expression of scavenger receptors, class A (SR-A). In these cells, adiponectin reduces lipopolysaccharides stimulated TNF-alpha production.
In some recent studies, adiponectin has a positive effect in endothelial homeostasis. It acts as a regulator of the enzyme endothelial nitric oxide synthase (eNOS), which is a key determinant of endothelial function and angiogenesis (the production of NO inhibits the infl ammatory response in the arteries), and also promotes phosphorylation of eNOS in endothelial cells, increases its expression and induces NO production after suppression of its activity caused by the effect of oxidized low-density lipoproteins (oxLDL). 8 There is an increasing number of papers on experimental models that point to the fact that adiponectin plays an important protective role in the development of insulin resistance and diabetes. Severe insulin resistance was seen in adiponectindefi cient knockout mice (KOAD) after administration of high fat and/or carbohydrates diets. Administration of adiponectin led to reduced hyperglycemia in the diabetic mice without affecting insulin levels. In another study, increased muscle fatty acid oxidation and reduction of plasma glucose, free fatty acids and triglycerides were observed. Studies on experimental animal models have revealed that the administration of adiponectin has a benefi cial action against the development of obesity and atherosclerosis. It seems that adiponectin acts not ET-1 -endothelin-1; ATII -angiotensin II; oxLDL -oxidized low-density lipoproteins; MCP-1 -monocyte chemoattractant protein 1; SMC -smooth muscle cell; MMP -matrix metalloproteinase; EC -endothelial cell. only as a factor increasing insulin sensitivity, and the protective effect may result from its ability to suppress production of proinfl ammatory cytokines. 7 In vitro experiments revealed the physiological concentrations of adiponectin inhibited TNF-alpha induced expression of VCAM-1 and ICAM-1 on the endothelium and exhibited other antiatherogenic effects. In 2008, Vaverková et al. published a study investigating the relationship between adiponectin and serum concentrations of soluble adhesive molecules VCAM-1 and ICAM-1 as well as with markers of insulin resistance and infl ammation in patients with cardiovascular disease (CVD) and in dyslipidemic patients at high risk of CVD. 9 The authors found signifi cant independent positive association of adiponectin with VCAM-1 but not with ICAM-1 serum concentrations in patients with or at risk for CVD. Their expression results in adhesion of circulating leukocytes to the endothelial cells and their subsequent transendothelial migration -an important step in initiation and progression of atherosclerosis.VCAM-1 and ICAM-1 have a different expression pattern and probably different roles in atherogenesis. 10 Soluble forms of these molecules can be measured in peripheral circulation. The origins of circulating soluble cell adhesion molecules are not entirely clear, but they may derive from shedding or proteolytic cleavage from endothelial cell.
Many studies, including experiments in vitro, animal models and studies in human, have shown that adiponectin has antiatherogenic and anti-infl ammatory properties. Low adiponectin levels were found in patients with coronary artery disease (CAD) independently of other risk factors. Therefore, the fi nding of positive and independent association of adiponectin with the marker of endothelial dysfunction VCAM-1 was surprising. This positive association was present both in patients with CVD and dyslipidemic subjects without CVD, but it was not signifi cant in healthy subjects without dyslipidemia. The authors hypothesize that adiponectin, which accumulates in the arterial wall only in place of endothelial injury and atherosclerotic plaques (that is the same places where VCAM-1 is expressed) may be involved in shedding of ectodomains of VCAM-1 from endothelial surface. This may represent a mechanism by which VCAM-1 effects on the cell surface can be downregulated. In this way, adiponectin could protect vascular wall from adhesion of leukocytes and thus from progression of atherosclerosis. 11
LEPTIN AND ENDOTHELIAL DYSFUNCTION
Leptin was one of the fi rst proteins discovered to be secreted from adipose tissue, by the identifi cation and sequencing of the ob gene from the ob/ ob mouse. Daily injection of the peptide in ob/ob mice resulted in a rapid reduction in food intake, body mass and percentage body fat but maintained lean muscle mass, increased energy expenditure and restored euglycaemia and reproductive function, confi rming that it has an important role in energy homoeostasis and storage. However, leptin levels were found to be increased in obese subjects, with little or no impact to regulate energy homoeostasis, which coined the well-established phrase 'leptin resistance' in obesity. 12 Leptin has been implicated in various pathophysiological mechanisms for CVD development. Hyperleptinemia has been linked with the development of hypertension and ED/atherosclerosis 13, 14 , two main pathophysiological conditions associated with CVD development (Fig. 2) .
MECHANISMS OF ED/ATHEROSCLEROSIS IN A STATE OF HYPERLEPTINEMIA

HYPERLEPTINEMIA ACTIVATES THE SYMPATHETIC NERVOUS SYSTEM (SNS) AND/OR ET-1
It has been demonstrated that experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. Leptin binds to its receptors in various regions of the central nervous system (CNS) -including the hypothalamus -activating neural pathways, decreasing appetite, and increasing SNS activity and energy expenditure. SNS activation by leptin may occur through both local peripheral actions and centrally mediated effects on the hypothalamus -although intact leptin receptors (LRs) and CNS signaling are still required for this response. 15 Leptin-mediated increases in SNS activity may be among the principal mechanisms evoking obesity-related hypertension.
ET-1 is a 21-amino acid peptide that is mainly produced by the vascular endothelium through the actions of an endothelin-converting enzyme on the endothelial cell membrane. ET-1 causes prolonged smooth muscle-mediated vasoconstriction and hypertension, affects cardiac stimulation in a manner that can indirectly modify cardiovascular function, stimulates aldosterone secretion, decreases renal blood fl ow and glomerular fi ltration rate, and releases atrial natriuretic peptide. Because of its powerful vasoconstrictor properties and its effects on intracellular calcium, ET-1 has been implicated in the pathogenesis of hypertension, coronary vasospasm, and heart failure. Leptin has been shown to induce ET-1 in endothelial cells in vitro, and stimulates ET-1 activity in lean subjects in vivo. 16 
LEPTIN AND INFLAMMATION
Several reports have also demonstrated that leptin possesses proinfl ammatory cytokine-like properties. It has been demonstrated that high plasma leptin levels up-regulate the expression of monocyte cytokines such as TNF-alpha and IL-6. 17 Leptin levels are also correlated with CRP in both lean and obese subjects. Furthermore, CRP can impact atherosclerosis development by hampering endothelial NO production -either directly by decreasing endothelial NO expression, or indirectly by increasing ROS production and thus inactivating NO. Leptin may regulate CRP production in the liver both through its effects on IL-6 and by direct regulation. 18 LEPTIN AND OXIDATIVE STRESS ROS production is enhanced in obesity. Leptin induces oxidative stress in human endothelial cells and mitochondrial superoxide anion production in aortic endothelial cells via augmented fatty acid oxidation. Excess superoxide production may quench NO, thus favoring the formation of ONOO-, which reduces local NO bioavailability. 19 This may result in the attenuation of dilator responses to NO-mediated agonists, such as acetylcholine (Ach).
HYPERLEPTINEMIA MAY INCREASE VASCULAR TONE AND IMPAIR VASODILATATION
The results regarding the overall effect of leptin on blood pressure have been controversial. It is likely that, with only short exposures, the leptinmediated increase in SNS activity may not be suffi cient to cause marked peripheral vasoconstriction and to acutely raise blood pressure. Additionally, impaired leptin-induced NO production might be compensated by endothelium-derived hyperpolarizing factor (EDHF). However, chronic increases in plasma leptin, comparable to those found in severe obesity, can raise blood pressure. This effect is partly because the contribution of EDHF to the hemodynamic effect of leptin becomes ineffi cient, as well as partly due to the activation of leptininduced renal mechanisms. 20 In fact, some studies have demonstrated that long-term leptin administration increases both renal sympathetic nerve activity and blood pressure, promoting sodium retention and decreasing natriuresis. 21 However, in lean rats, leptin-mediated increase of renal sodium excretion was not followed by blood pressure changes. It has been proposed that the lack of effect after acute leptin administration in vivo is related to the concept of selective leptin resistance and the "counterbalance theory". According to this theory, under normal physiological conditions in vivo, the simultaneous vasodilatory and vasopressor effects of leptin counteract each other, making leptin's net hemodynamic effect neutral. 22 However, in obese hyperleptinemic individuals or subjects with previous endothelial damage, this balance could be disrupted. In such cases, hyperleptinemia may alter vasodilatation capacity and raise blood pressure through SNS activation 15 and proinfl ammatory effects 17 , along with co-existing impairment of NO synthesis or NO activity. Following this reasoning, the acute effects of leptin would include both vasodilator effects together with SNS stimulation, resulting in an overall neutral effect.
Leptin has also been associated with hypertension via other mechanisms; for example, leptin increases ROS generation in endothelial cells, which decreases the amount of bioactive NO. As mentioned earlier, leptin stimulates the secretion of proinfl ammatory cytokines such as TNF-alpha and IL-6, and increases the release of ET-1, which may promote hypertension. Interestingly, one study demonstrated a reduction in serum leptin levels with the use of angiotensin-converting-enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), suggesting a potential interaction between leptin and the ROS for hemodynamic regulation in obesity. 21 
ADMA AND ENDOTHELIAL DYSFUNCTION
Endothelial dysfunction, a systemic disorder and an early pivotal event in the pathogenesis of atherosclerosis, is characterized by reduced production of nitric oxide (NO) and an imbalance between endotheliumdependent vasodilatation and vasoconstriction as well as antithrombotic and prothrombotic factors. NO maintains the vasodilatory property of endothelium and opposes the effects of such vasoconstrictors like ET-1 and angiotensin II (ANG II). It inhibits leukocyte and platelet activation and aggregation and, together with prostacyclins, helps to maintain the endothelium as a smooth nonthrombotic barrier. 23 The asymmetric dimethylarginine (ADMA), a by-product of cellular protein turnover, serves as a physiological regulator of the biosynthesis of NO and is believed to be an endogenous competitive inhibitor of eNOS. It is proved that increased serum levels of ADMA promote the process of atherosclerosis, leading to the occurrence of ED and CVD. 24 Elevated plasma levels of ADMA were demonstrated in patients with diabetes, hypercholesterolemia, hypertriglyceridemia, hypertension, preeclampsia, peripheral vascular disease, congestive heart failure, acute coronary syndrome. 25, 26 ADMA is perceived as a marker of ED, a candidate for a new cardiovascular risk factor or an independent risk factor for cardiovascular morbidity and mortality.
In a study of our clinic, which included 24 women with MS, 38 women with polycystic ovary syndrome (PCOS) and 24 age-matched clinically healthy women, we found significantly higher plasma levels of ADMA in both the women with PCOS and MS (0.91±0.32 μmol/l, and 0.82±0.37 μmol/l, respectively, p>0.05) as compared to those in the healthy women (0.65±0.35 μmol/l, p<0.05). No signifi cant correlations between ADMA and age, body mass index (BMI), waist circumference, fasting plasma glucose, fasting immunoreactive insulin (IRI), homeostasis model assessment of insulin resistance (HOMA-IR), lipid parameters and systolic blood pressure in the women with both MS and PCOS were found. In women with MS unlike those with PCOS, the diastolic blood pressure showed a signifi cant negative correlation with ADMA. 27 
CONCLUSION
Certain adipocytokines, such as leptin, TNF-alpha and adiponectin signifi cantly affect obesity-related metabolic diseases by controlling fat metabolism, energy homeostasis, and insulin sensitivity. Independent of their effects on glucose and fat metabolism, some adipokines have been regarded recently as direct links between obesity and atherosclerosis because of their infl uence on the function of endothelial cells (the production of NO), arterial smooth muscle cells, and macrophages in vessel walls. The interactions between the adipose tissue, the vascular wall, and the immune system are complex, and these are the key players from which we have to understand the mechanisms implicated in the development of atherosclerosis. In light of recent developments, interventions to decrease infl ammation associated with metabolic syndrome are actually developed and hopefully might in the near future be of great benefi t in decreasing the 'danger' associated with our modern lifestyle.
Патофизиологическая роль адипонектина, лептина и ассиметричного диметиларгинина в процессе атеросклероза
